April 16, 2018 / 7:44 PM / 5 months ago

BRIEF-Bristol-Myers Says FDA Approves Opdivo + Yervoy Combo For Treating Patients With Renal Cell Carcinoma

April 16 (Reuters) - Bristol-Myers Squibb Co:

* U.S. FOOD AND DRUG ADMINISTRATION APPROVES OPDIVO® (NIVOLUMAB) + YERVOY® (IPILIMUMAB) COMBINATION AS FIRST-LINE TREATMENT FOR PATIENTS WITH INTERMEDIATE- AND POOR-RISK ADVANCED RENAL CELL CARCINOMA

* BRISTOL-MYERS SQUIBB - IN PHASE 3 CHECKMATE -214 CLINICAL TRIAL, OPDIVO + YERVOY COMBINATION DEMONSTRATED A SIGNIFICANT INCREASE IN OVERALL SURVIVAL

* BRISTOL-MYERS SQUIBB - IN PHASE 3 CHECKMATE -214 TRIAL, OPDIVO + YERVOY ALSO DELIVERED DURABLE RESPONSES, WITH HIGHER OBJECTIVE RESPONSE RATE VERSUS SUNITINIB Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below